论文部分内容阅读
目的探讨肝动脉灌注细胞因子诱导杀伤(CIK)细胞联合超液化碘油(UFL)栓塞介入治疗原发性肝癌(HCC)的临床价值。方法采用Seldinger’s技术,经肝动脉灌注CIK细胞后用UFL栓塞肿瘤供血动脉治疗HCC 38例(研究组),并与同期经皮肝动脉灌注栓塞化疗(TACE)联合经皮瘤体注射无水乙醇(PEI)双介入治疗HCC 62例(双介入组)进行比较。结果研究组与双介入组治疗前后CD3、CD4、CD8变化的组间比较有差异(P(0.05);AFP的下降率,0.5,1和2年生存率,2组间差异有显著性(P(0.05);2组近期疗效组间比较无差异性(P>0.95)。结论肝动脉灌注CIK细胞联合UFL栓塞介入治疗HCC,可以延长患者的带瘤生存期。
Objective To investigate the clinical value of transcatheter hepatic arterial infusion of cytokine-induced killer (CIK) cells combined with transcatheter arterial chemoembolization (UFL) in the treatment of primary hepatocellular carcinoma (HCC). Methods Seldinger ’s technique was used to perfuse CIK cells through the hepatic artery and embolize the tumor feeding artery with UFL to treat 38 patients with HCC (study group). The percutaneous transhepatic arterial infusion chemoembolization (TACE) PEI) double interventional treatment of HCC 62 cases (double intervention group) for comparison. Results There were significant differences in the changes of CD3, CD4 and CD8 between study group and double-intervention group before and after treatment (P (0.05); AFP decline rate, 0.5, 1 and 2 year survival rate, the difference was significant (P0.05) .There was no significant difference between the two groups (P> 0.95) .Conclusion Intervention of hepatic artery perfusion with CIK cells and UFL embolization can prolong the tumor-bearing survival of patients with HCC.